Benvenue Medical, Inc., a Santa Clara, California-based developer of minimally invasive solutions for spine repair, has completed a $25m Series D financing.
Backers include existing investors DeNovo Ventures, Domain Associates, Technology Partners and Versant Ventures.
The company intends to use the funds to sustain global commercialization of its three minimally invasive products to treat degenerative disc disease (DDD) with spinal fusion and vertebral compression fractures (VCFs), as well as for additional initiatives to bring its fusion and VCF products to the US market.
Founded in 2004 and led by CEO Robert Weigle, Benvenue Medical offers:
– the Kiva VCF Treatment System, distributed by Zimmer Spine in Europe and evaluated in the KAST (Kiva® System as a Vertebral Augmentation Treatment – A Safety and Effectiveness Trial) clinical trial, which is being conducted in support of 510(k) market clearance from the U.S. Food and Drug Administration (FDA);
– the Blazer™ Vertebral Augmentation System, also used in treating VCFs, commercially available in the U.S.
– the Luna™ Interbody Spacer System for spinal fusion procedures, which received CE Mark approval in 2010 and is currently enrolling patients in a European post-market study, the Luna Interbody System for Fusion Trial (LIFT).